Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CCNK | O75909 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4648713 | 0.87 | CNR2 (0.54) | CNR2CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL14065126 | 0.83 | CNR2 (0.42) | CNR2CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4649002 | 0.83 | CNR2 (0.44) | CNR2CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4649611 | 0.82 | CNR2 (0.54) | CNR2CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4648729 | 0.82 | CNR2 (0.69) | CNR2CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL30730223 | 0.71 | PRMT5 (0.71) | CYP1A2PRMT5WDR77CYP2D6CYP2C9 | |
| SCHEMBL4650498 | 0.69 | CNR2 (0.70) | CNR2CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4932814 | 0.69 | CNR2 (1.00) | CNR2CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL14005882 | 0.69 | CNR2 (0.69) | CNR2CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4923994 | 0.67 | CNR2 (0.70) | CNR2CYP1A2CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280868-A1 | Pyridine Derivatives and Their Use as Cb2 Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080280868-A1 | Pyridine Derivatives and Their Use as Cb2 Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080280868-A1 | Pyridine Derivatives and Their Use as Cb2 Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| EP-1718613-B1 | PYRIDINE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2008-09-03 | — | — | EP | disclosed |
| EP-1718613-B1 | PYRIDINE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2008-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280868-A1 | Pyridine Derivatives and Their Use as Cb2 Receptor Modulators | CNR2, CNR1, TRPV1 | CNR2 1/4885CYP1A2 306/4885PRMT5 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.